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Abstract 
 
Proteins of the NSD family are histone-methyl transferases with critical functions in the regulation 
of chromatin structure and function. NSD1 and NSD2 are homologous proteins that function as 
epigenetic regulators of transcription through their abilities to catalyse histone methylation. 
Misregulation of NSD1 and NSD2 expression or mutations in their genes are linked to a number of 
human diseases such as Sotos syndrome, and cancers including acute myeloid leukemia, multiple 
myeloma, and lung cancer. The catalytic domain of both proteins contains a conserved SET domain 
which is involved in histone methylation. Here we report the backbone resonance assignments and 
secondary structure information of the catalytic domains of human NSD1 and NSD2.  
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Biological context 
The nuclear SET domain (NSD) containing proteins are a family of mammalian histone-methyl 
transferases with diverse functions in cell growth and differentiation. This family comprises NSD1, 
NSD2 (also known as MMSET/WHSC1) and NSD3 (also known as WHSC1L1). These proteins 
are emerging as important therapeutic targets in the epigenetic therapy of cancers. Members of the 
NSD family, all of which contain a conserved Su(var) 3-9, enhancer of zeste, trithorax (SET) 
domain, act to methylate specific lysine residues on histone tails (Huang et al. 1998, Li et al. 2009, 
Rayasam 2003, Varier and Timmers 2010). This serves as an epigenetic marker for the recruitment 
of various complexes controlling chromatin organisation and gene expression. Both NSD1 and 
NSD2 regulate methylation of lysine 36 on histone 3, a process which is crucial to chromatin 
regulation. In addition, both NSD1 and NSD2 have been shown to regulate methylation of lysine 20 
on histone 4 and the non-histone p65 subunit of nuclear factor-ț%1)-ț%Berdasco et al. 2009, 
Lu et al. 2010, Rayasam et al. 2003, Wang et al 2007, Pei et al 2011). Aberrant expressions of 
NSD1 and NSD2 are associated with multiple types of cancer, including acute myeloid leukemia, 
multiple myeloma, and lung cancer (Jaju et al. 2001, Keats et al 2003, La Starza et al. 2004, Tonon 
et al. 2005, Wang et al. 2007). In addition to its role in cancer, mutations or alterations to the NSD1 
gene are responsible for a number of developmental disorders, including Sotos and Weaver 
syndromes (Douglas et al. 2003). 
Both NSD1 (2696 residues) and NSD2 (1365 residues) contain a number of functional domains, 
including a catalytic domain, two proline-tryptophan-tryptophan-proline (PWWP) domains, four 
zinc-finger plant homeodomains (PHDs), and two nuclear receptor interaction domains (Kurotaki et 
al. 2001, Qiao et al. 2011). The catalytic domain, which is responsible for histone methylation, is 
itself comprised of a SET domain and two cysteine-rich flanking domains; an N-teminal pre-SET 
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domain and a C-terminal post-SET domain. Although no tertiary structure yet exists for NSD2, the 
structure of the catalytic domain of NSD1 has been solved (Qiao et al. 2011). The SET domain is 
approximately 130 amino acids in length and contains adjacent binding sites for the lysine-[histone] 
ligand and the cofactor S-adenosylmethionine (SAM), which acts as a methyl group donor. The 
post-SET domain forms one side of the SAM binding pocket and is crucial for the catalytic 
competency of the enzyme. The loop connecting the SET and post-SET domains (the post-SET 
loop) is able to block the substrate-lysine binding site and regulate substrate binding.  
The high sequence similarity between the catalytic domains of NSD1 and NSD2 (76% identity) 
indicates a similar overall topology, with pre-SET, SET and post-SET domains. Despite these 
structural insights on NSD1 and NSD2, the molecular bases of substrate specificity and catalysis are 
not fully understood. Here we report the backbone 1H, 15N and 13C assignment of the catalytic 
domains of human NSD1 (residues 1852 ± 2082) and NSD2 (residues 973 - 1203) and their 
secondary structure. 
 
Methods and exper iments  
Protein expression and purification 
 
The catalytic domains of human NSD1 (residues 1852 -2082) and NSD2 (residues 973-1203) were 
each produced with a TEV protease-cleavable His-tag at the N-terminus. These constructs were 
subcloned into pET23b vectors and overexpressed in E. coli Bl21 cells. Cleavage of the His-tag 
resulted in an additional three residues at the N-terminus (GSH).  Uniformly 15N-labelled and 
15N/13C-labelled protein were expressed in minimal medium supplemented with either 15NH4Cl (1 
g/l) or 15NH4Cl (1 g/l) and 13C-glucose (2 g/l) as the sole nitrogen and carbon sources, respectively. 
Unlabelled protein was expressed in Terrific Broth (TB). Cells were grown at 37 °C to an optical 
density at 600 nm of 0.5 and expression was induced with 1 mM IPTG. The cells were incubated at 
15 °C for 16 hours. Cells were lysed by sonication and purified by immobilised metal affinity 
chromatography. The His-tag was removed using TEV protease and the proteins were further 
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purified by size-exclusion chromatography. The proteins were then concentrated and dialysed 
against the appropriate NMR buffer. 
N M R spectroscopy: 
 
The NMR data were acquired at either Astex Pharmaceuticals or the Department of Biochemistry, 
8QLYHUVLW\ RI&DPEULGJH (DFK105 VDPSOHZDVPDGH XS WR D YROXPH RI  ȝO LQ D PP
capillary which was placed in a standard 5 mm NMR tube. At Astex Pharmaceuticals, experiments 
were carried out at 310 K unless otherwise stated, using a Bruker Avance III 500 MHz spectrometer 
equipped with a 5 mm TXI cryoprobe. NMR spectra were processed using TOPSPIN and analysed 
using either TOPSPIN or CCPN Analysis (Vranken et al. 2005). At the Department of 
Biochemistry, University of Cambridge, experiments were carried out at 310 K on a Bruker Avance 
III spectrometer equipped with a 5 mm QCI HFCN/z cryoprobe operating at a 1H frequency of 600 
MHz. The data was collected with non-uniform sampling (10% of the full matrix were sampled). 
The 3D spectra were reconstructed using the maximum entropy module implemented in the Azara 
processing software (W. Boucher, unpublished).  
The folded state and stability of NSD1 and NSD2 catalytic domains were initially assessed using 
1H-15N HSQC NMR spectra. The best quality spectra, as judged by line-widths and number of 
peaks, was obtained for both proteins at 310 K, with a saturating concentration of the co-factor 
SAM (2 mM). However, both proteins became significantly degraded at this temperature within a 
few hours. A number of buffer conditions were therefore tested for their effects on protein stability 
at 310 K. Protein stability was assessed by 1D proton NMR spectroscopy using unlabelled protein, 
by observing the attenuation of methyl and amide peaks in the 1D spectra over time. For the 1D 1H 
NMR stability screen, all experiments were carried out using unlabelled protein at a concentration 
RIȝ0ZLWKP06$0DQGDWHPSHUDWXUHRI.7KHEXIIHUVXVHGZHUHHLWKHUP0 MES 
or sodium phosphate, pH 6 or 6.5 and a range of salt (NaCl) concentrations between 150 and 450 
ȝ0 
The backbone 1H, 13C and 15N resonances of NSD1 and NSD2 catalytic domains were assigned 
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using 13C/15N- uniformly-labelled protein at a concentration oIȝ0)RU16'WKH105EXIIHU
used was MES 50 mM pH 6.5, NaCl 450 mM, TCEP 2 mM, SAM 2 mM, NaN3 0.01% w/v, D2O 
10% v/v. For NSD2 the NMR buffer was sodium phosphate 50 mM pH 7, NaCl 450 mM, TCEP 2 
mM, SAM 2 mM, NaN3 0.01% w/v, D2O 10% v/v. The protein was split into several aliquots which 
were stored at -20º C. Because of the poor stability of both proteins at 310 K, each sample was kept 
in the spectrometer at 310 K for a maximum of 2 days and was replaced with a fresh sample if 
necessary. The experiments were recorded at the Department of Biochemistry, University of 
Cambridge and were a combination of standard triple resonance experiments; a 2D 1H-15N HSQC, 
and 3D HNCO, HNCA, HN(CO)CA, HN(CO)CACB and HNCACB experiments (Sattler et al. 
1999). Except for the HNCO all experiments were repeated several times (2-3 times) using fresh 
samples and the spectra co-added to improve the overall sensitivity. 
 
 
Methods and exper iments  
Extent of assignments and data deposition 
Figures 1 and 2 show the 1H-15N HSQC spectra at 310 K of the catalytic domains of human NSD1 
and NSD2, respectively. The spectra indicate that both proteins are well-folded. Each construct 
contains an additional four residues at the N-terminus, which were part of the hexahistidine tag that 
remained on the protein following cleavage of the tag. These residues were not assigned and are 
therefore not identified in either HSQC spectrum. For NSD1, 212 of the 219 non-proline amide 
residues (96.8%) of the catalytic domain were assigned. 97.8% RIWKH&ĮUHVRQDQFHVRIWKH
&ȕUHVRQDQFHVDQGRIWKHFDUERQ\O&UHVRQDQFHVZHUHDVVLJQHG)RU16'RIWKH
non-SUROLQH DPLGH UHVLGXHV RI WKH FDWDO\WLF GRPDLQ ZHUH DVVLJQHG     RI WKH &Į
UHVRQDQFHVRIWKH&ȕUHVRQDQces and 88.8 % of the carbonyl C resonances were assigned. 
The chemical shifts have been deposited in the BioMagResBank (http://www.bmrb.wisc.edu) under 
accession numbers 26767 and 26768 for NSD1 and NSD2 respectively. For NSD1, seven residues 
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of the core construct could not be assigned (Q1858, G1929, L1950, Q1951, C2022, C2023 and 
Q2024). Most of these resonances appear to be broadened beyond detection in the 3D experiments, 
suggesting conformational exchange on an intermediate timescale in these regions. With the 
exception of Q1858 and G1929, these residues are situated on loops in the SET domain adjacent to 
the SAM binding site. The deviations in backbone 13&ĮDQG13&ȕFKHPLFDOVKLIWVIURPUDQGRPFRLO
values are shown in figure 3. These are broadly consistent with the secondary structure of the 
crystalline protein (Qiao et al. 2011). 
 
 
Secondary structure determination 
The two protein sequences are highly similar. A pairwise sequence alignment using the Needleman 
and Wunsch algorithm (Needleman and Wunsch, 1970) (figure 3) yielded 76.3% identity and 
89.2% similarity over 232 residues. Indeed, the similarity was such that no gaps were introduced 
into the alignment. Figure 3 shows the secondary structures of both proteins, derived from their 
backbone chemical shifts. Also shown in this figure is the secondary structure of human NSD1, as 
determined from its crystal structure (PDB ID 300I) (Qiao et al. 2011). The NMR-derived 
secondary structures of both proteins correspond well with the expected fold for the catalytic 
domain, with a core SET domain motif composed of three beta sheets with an alpha-helix adjacent 
to the second beta sheet. This core SET domain is flanked by an N-terminal helix adjacent to beta 
sheet 1 and the AWS domain at the other end, adjacent to beta-sheet 3. 
There is broad general agreement between the NMR-derived secondary structures of the two 
proteins, with the exception of the N-terminus, which is less well defined in NSD2. The NMR-
derived secondary structures agree well with the secondary structure of NSD1 derived from the 
crystal structure. The two proteins are therefore expected to have a similar topology and fold, with 
no major structural differences between them. It is hence postulated that difficulties encountered 
during crystallisation of NSD2 are due to increased conformational flexibility of this protein 
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compared to NSD1.  
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F igure 1. 1H-15N HSQC spectrum of human NSD1 catalytic domain. The spectrum was recorded 
using 200 µM 13C-15N-labelled protein at 600 MHz. Residue assignments are indicated.  For the 
sake of clarity, a number of peaks are shown annotated separately. 
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0DUGRF[
F igure 2. 1H-15N HSQC spectrum of human NSD2 catalytic domain. The spectrum was recorded 
using 200 µM 13C-15N-labelled protein at 600 MHz. Residue assignments are indicated.  For the 
sake of clarity, a number of peaks are shown annotated separately 
 
F igure 3. Sequence alignment between NSD1 and NSD2, illustrating similarities in secondary 
structure. Alpha-helices and beta-sheets are depicted as black and grey squares, respectively. In 
each block: Rows 1 and 2 show the sequences of NSD1 and NSD2 respectively.  Rows 3 and 4 
show the secondary structure of NSD1 as derived from the crystal structure. These have been 
defined using the programs DSSP (Kabsch and Sander, 1983) (row 3) and STRIDE (Heinig and 
Frishman, 2004) (row 4). Rows 5 and 6 contain the NMR-derived secondary structure of NSD1, 
calculated using the programs CSI (Hafsa and Wishart 2014) and DANGLE (Cheung, Maguire et. 
al., 2010), respectively. Rows 7 and 8 contain the NMR-derived secondary structure of NSD2, 
calculated using the programs CSI and DANGLE, respectively. 
 
 
 
